Standalone Q2 revenue up 19%, profit up 22%; six-month profit up 28%

Emphasis Of MatterResults RestatedEbitda Margin ExpansionPat Growth 25pctResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2212.60

prior close

₹2285.20

announcement price

In-mkt

timing

Nifty Midcap 150market+1.1%+3.4% vs market

Pharmaceuticals peers, median of 174sector+1.2%+3.3% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Midcap 150 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.2

15m

+1.2

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+1.1+3.4+1.2+3.3

Next day

+13.1+2.0+11.1+3.1+10.0

+12.5+2.3+10.2+4.7+7.8

+11.6+3.2+8.4+4.7+6.9

+12.7pendingpending+3.2+9.4

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 consolidated revenue was Rs 4,337.86 crore and profit after tax of Rs 716.12 crore. Standalone revenue rose 19.3% and profit after tax rose 22.4%; six-month profit rose 27.9% to Rs 1,140.44 crore. Operating margin improved to 30% from 27%. Auditors flagged pending tax cases involving Rs 1,868.89 crore of disputed additions. Prior figures were restated after a Rs 797 crore women's health deal. Two internal merger plans await approvals.

Likely market impact

Profit growth supports sentiment, but tax cases and pending merger approvals may cap gains. The debt-to-equity ratio remains low at 0.26.